Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025
상품코드:1810915
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 CAGR 4.6%로 15억 7,000만 달러로 성장합니다. 예측 기간의 성장은 분자진단 실험실의 가용성 확대, 위암 검진에 대한 의식의 향상 캠페인 증가, 차세대 염기서열 분석(NGS) 사용 증가, 외래 암 치료 서비스에 대한 수요 증가, HER2 표적 치료제의 세계 규제 승인 증가에 의해 이루어질 것으로 예측됩니다. 이 기간의 주요 동향으로는 치료 순서의 최적화, 약물전달에 나노테크놀러지 적용, HER2 진단에 인공지능 활용, 항체 의존성 세포독성 강화, 면역요법 병용요법의 발전 등이 있습니다.
암 표적치료제 사용 확대가 인간상피세포성장인자수용체2(HER2) 양성 위암 시장의 성장을 촉진할 것으로 예측됩니다. 표적치료는 맞춤의료라고도 불리는데, 종양 발생에 관여하는 특정 분자에 초점을 맞추어 암의 증식을 억제하는 치료법입니다. 이 접근법은 유전자 프로파일링의 발전으로 환자 개개인의 종양 특성에 맞는 치료가 가능해지면서 많은 지지를 받고 있습니다. HER2 양성 위암의 경우, 표적치료제는 이러한 종양에서 과발현된 HER2 단백질을 특이적으로 공격하여 질병의 진행을 지연시키고 환자의 예후를 개선하는 데 도움을 주고 있습니다. 예를 들어 2024년 2월, 맞춤형 의료 연합은 미국 식품의약국(FDA)이 2023년 16개의 새로운 개인화 의약품을 승인했다고 보고했습니다. 그 내역은 암치료제가 7종, 기타 다양한 질환치료제가 3종으로 2022년 6종에서 증가했습니다. 이러한 추세는 암 치료에서 표적치료제의 역할 확대와 HER2 양성 위암 시장 확대에 대한 기여를 지원하고 있습니다.
HER2 양성 위암 분야 기업은 새로운 치료법, 특히 면역요법, 표적치료제, 화학요법을 통합한 병용요법의 승인 획득을 우선순위로 삼고 있습니다. 이러한 첨단 치료법은 면역관문억제제를 사용하여 PD-1 또는 PD-L1 경로를 억제하는 동시에 HER2 수용체를 표적으로 하는 화학요법을 적용함으로써 1차 치료 시나리오에서 환자의 예후를 개선하는 것을 목표로 하고 있습니다. 이 접근법은 항종양 활성을 높이고 생존율을 향상시킵니다. 2025년 3월, 미국 바이오 제약사 머크 앤 컴퍼니(Merck & Co., Inc.)는 트루스투주맙과 화학요법과 병용하는 펨브롤리주맙(키트루다)에 대한 FDA 승인을 획득했습니다. 이 치료제는 PD-L1을 발현하는 HER2 양성 절제불능 또는 전이성 위암 또는 위식도 접합부 선암 성인 환자를 대상으로 승인되었습니다. 임상시험 결과, 이 병용요법은 무진행생존기간과 전체생존기간의 중앙값을 유의하게 개선시켰으며, 반응률은 73%, 반응기간의 중앙값도 연장시켰습니다. 이번 승인은 HER2 양성 진행성 위암 치료에 있으며, 큰 진전입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 성장률 분석
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 실적 : 규모와 성장, 2019-2024
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 테라피별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
화학요법
면역치료
방사선 치료
표적치료
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 스테이지별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
스테이지 I
스테이지 II
스테이지 III
스테이지 IV
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외래 수술 센터
병원과 전문 클리닉
기타 최종사용자
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 서브 세분화, 화학요법(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Fluoropyrimidines
Platinum-Based Agents
Taxanes
Irinotecan
Anthracyclines
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 서브 세분화, 면역치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
면역 체크포인트 저해제
모노클로널 항체
암 백신
사이토카인 기반 치료법
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 서브 세분화, 방사선 요법의 유형, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외부 방사선 요법
강도 변조 방사선 치료
정위방사선 치료
3D 컨포멀 방사선 치료
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 서브 세분화, 표적치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
HER2 표적치료
티로신 키나아제 저해제
항체약물접합체
mTOR 저해제
PI3K/AKT/mTOR 경로 저해제
제7장 지역별·국가별 분석
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 경쟁 구도
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Bristol-Myers Squibb Company
AstraZeneca PLC
Novartis AG
Amgen Inc.
Astellas Pharma Inc.
Daiichi Sankyo Company Limited
Genentech Inc.
Ono Pharmaceutical Co Ltd.
Shanghai Henlius Biotech Inc.
MacroGenics Inc.
Hutchison Medipharma Limited
ALX Oncology Holdings Inc.
Taiho Pharmaceutical Co Ltd.
Ambrx Biopharma Inc.
LintonPharm Co Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 2029 : 새로운 기회를 제공하는 국가
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 2029 : 새로운 기회를 제공하는 부문
인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a form of stomach or gastroesophageal junction cancer characterized by an overexpression of the HER2 protein or amplification of the HER2 gene, which drives cancer cell growth. This subtype is responsive to specific targeted therapies, leading to improved outcomes for suitable patients.
The primary treatment options for HER2-positive gastric cancer include chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy involves the use of potent drugs that circulate through the bloodstream to kill rapidly dividing cancer cells, including those in HER2-positive gastric cancer. It is applied across different cancer stages, such as stage I through stage IV, and is utilized by various healthcare providers including ambulatory surgery centers, hospitals, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market statistics, including human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry global market size, regional shares, competitors with a human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market share, detailed human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry. This human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.25 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. Growth during the historic period was driven by the increased use of companion diagnostics, greater awareness among oncologists regarding HER2 biomarkers, a stronger emphasis on personalized cancer treatments, growing interest in antibody-drug conjugates, and enhanced reimbursement policies for targeted therapies.
The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. Growth in the forecast period is expected to result from the expanding availability of molecular diagnostic laboratories, increased awareness campaigns for gastric cancer screening, rising use of next-generation sequencing (NGS), growing demand for outpatient cancer care services, and more global regulatory approvals of HER2-targeted drugs. Key trends during this period include optimizing treatment sequencing, applying nanotechnology in drug delivery, utilizing artificial intelligence in HER2 diagnostics, enhancing antibody-dependent cellular cytotoxicity, and advancing immunotherapy combination approaches.
The increasing use of targeted cancer therapy is expected to drive growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market. Targeted therapy, often referred to as personalized medicine, involves treatments that block cancer growth by focusing on specific molecules involved in tumor development. This approach has gained traction due to advancements in genetic profiling, which make it possible to tailor treatments to the individual characteristics of a patient's tumor. In the case of HER2-positive gastric cancer, targeted therapies specifically attack the HER2 protein, which is overexpressed in these tumors, helping to slow disease progression and improve patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023. These included seven cancer drugs and three others for various conditions, up from six in 2022. This trend supports the growing role of targeted therapies in cancer treatment and their contribution to the expansion of the HER2-positive gastric cancer market.
Companies in the HER2-positive gastric cancer space are also prioritizing regulatory approvals for new therapies, particularly combination treatments that integrate immunotherapy, targeted therapy, and chemotherapy. These advanced regimens aim to improve patient outcomes in first-line treatment scenarios by using immune checkpoint inhibitors to block PD-1 or PD-L1 pathways while concurrently targeting HER2 receptors and applying chemotherapeutic agents. This approach enhances anti-tumor activity and improves survival rates. In March 2025, Merck & Co., Inc., a U.S.-based biopharmaceutical company, received FDA approval for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy. This treatment is approved for adults with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. Clinical results showed this combination significantly improved median progression-free survival and overall survival, with a response rate of 73% and a longer median duration of response. The approval marks a major advancement in managing advanced HER2-positive gastric cancer.
In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. to enhance its portfolio of oncology therapies. This acquisition was intended to strengthen Pfizer's capabilities in the development and delivery of targeted cancer treatments. Seagen Inc. is a U.S.-based biotechnology company known for its specialization in therapies for HER2-positive gastric cancer.
Major players in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on human epidermal growth factor receptor 2 (her2)-positive gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Targeted Therapy
2) By Stage: Stage I; Stage II; Stage III; Stage IV
3) By End-User: Ambulatory Surgery Centers; Hospitals And Specialty Clinics; Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines; Platinum-Based Agents; Taxanes; Irinotecan; Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Cancer Vaccines; Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy; Intensity-Modulated Radiation Therapy; Stereotactic Body Radiation Therapy; 3D Conformal Radiation Therapy
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Characteristics
3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Strategies
4. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Rate Analysis
5.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Total Addressable Market (TAM)
6. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation
6.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy
6.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stage I
Stage II
Stage III
Stage IV
6.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambulatory Surgery Centers
Hospitals And Specialty Clinics
Other End-Users
6.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluoropyrimidines
Platinum-Based Agents
Taxanes
Irinotecan
Anthracyclines
6.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cancer Vaccines
Cytokine-Based Therapies
6.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy
Intensity-Modulated Radiation Therapy
Stereotactic Body Radiation Therapy
3D Conformal Radiation Therapy
6.7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HER2-Targeted Therapies
Tyrosine Kinase Inhibitors
Antibody-Drug Conjugates
mTOR Inhibitors
PI3K/AKT/mTOR Pathway Inhibitors
7. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional And Country Analysis
7.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
8.1. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
9.1. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
9.2. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
10.1. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
11.1. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
11.2. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
12.1. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
13.1. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
14.1. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
14.2. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
15.1. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
15.2. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
16.1. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
17.1. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
18.1. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
19.1. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
20.1. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
21.1. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
21.2. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
22.1. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
23.1. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
23.2. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
24.1. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
24.2. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
25.1. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
25.2. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
26.1. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
26.2. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
27.1. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
28.1. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
28.2. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
29.1. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
29.2. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Company Profiles
30.1. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape
30.2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
31. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. Novartis AG
31.4. Amgen Inc.
31.5. Astellas Pharma Inc.
31.6. Daiichi Sankyo Company Limited
31.7. Genentech Inc.
31.8. Ono Pharmaceutical Co Ltd.
31.9. Shanghai Henlius Biotech Inc.
31.10. MacroGenics Inc.
31.11. Hutchison Medipharma Limited
31.12. ALX Oncology Holdings Inc.
31.13. Taiho Pharmaceutical Co Ltd.
31.14. Ambrx Biopharma Inc.
31.15. LintonPharm Co Ltd.
32. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
34. Recent Developments In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market
35. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market High Potential Countries, Segments and Strategies
35.1 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Growth Strategies
